Aro Biotherapeutics

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.

Aro Biotherapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $13.3B in funding across 80 round(s). With a team of 11-50 employees, Aro Biotherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Aro Biotherapeutics, raised $41.5M. Discover more about their projects, partnerships, and impact on our platform.